This was supported by our recent finding that pharmacological abrogation of EGFR signalling in prostate carcinoma cells reverses decreased E-cadherin expression rendering these cells less invasive and more cohesive (Jawhari et al, 1999; Yates et al, 2005). The gene discussed is CDH1; the disease is prostate carcinoma.